Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

Hamdy A Azim,1 Ashraf Omar,2 Hesham Atef,1,† Heba Zawahry,3 Mohamed K Shaker,4 AH Kamel Abdelmaksoud,5 Mohamed EzzElarab,6 Omar Abdel-Rahman,7 Mohamed Ismail,8 Loay Kassem,1 Imam Waked9 1Department of Clinical Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt; 2Department of G...

Full description

Bibliographic Details
Main Authors: Azim HA, Omar A, Atef H, Zawahry H, Shaker MK, Abdelmaksoud AHK, EzzElarab M, Abdel-Rahman O, Ismail M, Kassem L, Waked I
Format: Article
Language:English
Published: Dove Medical Press 2018-11-01
Series:Journal of Hepatocellular Carcinoma
Subjects:
Advanced hepatocellular carcinoma
sorafenib
Tegafur/uracil
Egypt
Online Access:https://www.dovepress.com/sorafenib-plus-tegafur-uracil-uft-versus-sorafenib-as-first-line-syste-peer-reviewed-article-JHC

Internet

https://www.dovepress.com/sorafenib-plus-tegafur-uracil-uft-versus-sorafenib-as-first-line-syste-peer-reviewed-article-JHC

Similar Items